Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy during pregnancy

B. L. HERCULES, MARGARET WOZENCROFT, I. I. GAYED, AND JULIE JEACOCK

From the Royal Eye Hospital, Computational Group, Faculty of Medicine, University of Manchester, and Ahmadi Hospital, Kuwait Oil Company, Kuwait

SUMMARY The course of proliferative diabetic retinopathy involving the optic disc was followed, and the response to peripheral retinal photocoagulation monitored by argon laser in 11 patients during and after 13 pregnancies. Traditional obstetric practice assumes that pregnancy is a stimulus to irreversible progression of proliferative diabetic retinopathy, and that timely abortion and sterilisation are essential in order to achieve control of the neovascular process. Extensive photocoagulation will cause significant regression of neovascular complexes in 63% of cases, and it confers sufficient benefits to make ophthalmic indications for therapeutic abortion and sterilisation no longer tenable.

Taylor and Dobree\(^1\) stated that between 68 and 73.25% of patients presenting with proliferative diabetic retinopathy have neovascularisation involving the optic disc. In a 3-year study Beetham \textit{et al.}\(^2\) showed that 85% (28 patients) of untreated eyes with vitreous haemorrhage bled from new vessels at the optic disc. This group of patients, exhibiting neovascularisation of the optic disc, inevitably have the poorest prognosis. Consequent on haemorrhage one-third of involved eyes are blind and one-third have permanent impairment of vision within 1 year.\(^3\) This is the most serious potential hazard for visual prognosis;\(^4\) 50% of these diabetic patients are blind within 2 to 3 years. If one eye becomes blind, Patz and Berkow\(^5\) have shown that the second (good) eye follows rapidly (50% within 1 year).

New vessels in proliferative diabetic retinopathy tend to progress during 9 months of activity in many cases, and it is therefore difficult to assess the effect of pregnancy on the course of this process. Reports on the subject come to no firm or convincing conclusions, but the risk to vision of rapidly advancing retinopathy during pregnancy has been stated to be high. Diabetic patients have frequently been advised against pregnancy if retinopathy has been present.\(^6\) From 200 pregnant diabetics attending the Joslin clinic with ocular symptoms Beetham\(^7\) found 12 patients (18 pregnancies) with proliferative retinopathy and observed progression of the neovascular process in 4. Janert \textit{et al.}\(^8\) observed progression of retinopathy in all 6 of their patients. White\(^9\) described 87 pregnant diabetics with proliferative retinopathy: 10 showed haemorrhagic activity prior to or during the first trimester; 11 of the 20 eyes progressed to blindness. She noted that eye lesions may improve after delivery, and that abortion is indicated (i) when retinopathy is deteriorating and (ii) when blindness might be expected if the pregnancy is continued. This tendency to regression of proliferative retinopathy after delivery has also been observed by Lawrence,\(^10\) Stephens \textit{et al.},\(^11\) Janert \textit{et al.},\(^8\) and Laws \textit{et al.}\(^12\)

Driscoll and Gillespie\(^13\) considered advancing retinal neovascularisation, but not mere existence of retinopathy or blindness, an indication for termination of pregnancy. They also considered advanced retinopathy, and a high risk of ensuing blindness in the foreseeable future, constituted valid grounds for sterilisation.

Okun \textit{et al.}\(^14\) noted that in 6 out of 10 diabetic patients proliferative retinopathy progressed rapidly during pregnancy. After termination the rate of growth of new vessels lessened, but they regressed in only 1 case. Burt and Weaver\(^15\) reported 2 cases of proliferative retinopathy in successfully pregnant women. One improved only after delivery, when pituitary ablation was undertaken, and the other improved during the course of pregnancy. They concluded that patients should be managed individually rather than routinely recommended for therapeutic abortion. Kohner \textit{et al.}\(^16\) demonstrated that rapidly advancing proliferative retinopathy

Correspondence to Mr B. L. Hercules, FRCS, Manchester Royal Eye Hospital, Oxford Road, Manchester M13 9WH.
could be contained during pregnancy by photo-
coagulation and afterwards by pituitary ablation.

In view of the suggestions of other workers and
before any of their results were available a trial was
initiated in Manchester in 1973 to attempt elimina-
tion of optic-disc neovascularisation in the diabetic
patient by peripheral retinal ablation.17 During
the course of this study 5 pregnant women were
admitted and every attempt was made to contain
the proliferative process during their 6 pregnancies.
Subsequently 6 more pregnant patients with optic
disc neovascularisation were admitted to the group
to give a total of 11 women and 13 pregnancies.

Patients and methods

Five pregnant women were entered into a rando-
mised, controlled trial of 94 consecutive patients
with a reasonably symmetrical proliferative diabetic
retinopathy involving the optic disc. They had a
visual acuity which did not differ by more than 2
lines on the Snellen chart and was at least 6/24 in
the worse eye. Subsequently a further 6 women
with optic disc neovascularisation were grouped
with the women from the controlled trial. This
latter group either were receiving argon laser
photoagulation when they discovered they were
pregnant or commenced treatment soon after this
event. No patient was excluded from the study for
any of the reasons laid down in the study protocol.17

Technique

All treated eyes were subjected to extensive peri-
pheral retinal photoagulation by means of a
Coherent 800 gas-argon laser, incorporating a
3 mirror Goldmann lens in the delivery system18
when necessary. The procedure was well tolerated
after instillation of local anaesthetic drops in all
patients.

Photoagulation burns were applied within the
vascular arcades above and below the macula, but
an approximately circular area of radius 2.5 disc
diameters, with the fovea at its centre and including
the papillomacular bundle, was left untouched. In
the nasal fundus photoagulation was extended
centrally to the edge of the optic disc and involved
any new vessels arising from this margin. In all
meridians photoagulation was extended anteriorly
to the equator by means of the 3-mirror lens.

Individual burns with sufficient energy to accom-
plish minimal retinal blanching were applied so
that the observer achieved a uniform response over
the whole area being treated. Marker burns of
200 μm diameter were applied to delineate the
central area which was to be avoided. Inside the
vascular arcades the 200 μm spot diameter was
used. Outside the arcades and nasally, the 500 μm
spot diameter was used exclusively as far as the
periphery. In the nasal sector burns were applied
from the nasal edge of the optic disc to the equator
in radial rows which followed the direction of the
nerve fibres.

Energy levels between 0.2 and 0.6 watt were used,
though most burns required 0.35 to 0.45 watt.
Inferiorly higher energy levels were required than
in any other area of the retina. Lower energies of
0.2 watt were almost invariably adequate within the
macular vascular arcades of vessels, where the 200
μm spot was used. In other areas utilising the
500 μm spot levels up to 0.5 watt were usually
required. To complete treatment over 2000 burns
were applied to most patients (range 800 to 3000).
The procedure usually required up to 6 sittings
over a week.

Retreatment of areas which appeared unduly
lightly treated and of any patches of untreated
retina within the 'target' area of the ablation
procedure was undertaken in patients in whom
optic disc neovascularisation persisted.

Data recorded

Patients entering the trial received a full ophthalmic
assessment including refraction, tonometry, visual
fields, fundus photography, and fluorescein angi-
ography. Patients were not excluded from the study
group on the basis of nephropathy or other serious
extraocular diabetic problems. However, during
and after treatment every attempt was made to
achieve good diabetic control by careful medical
assessment. The eye to be treated was chosen at
random and the untreated eye recorded as a control.

Evaluation of treatment was based on four
main criteria: (1) Visual acuity: best corrected
visual acuities were obtained at each visit, on
subjective testing, by a refractionist who was not
aware of the previous visual acuity nor the treated
eye. (2) Appearance of the optic discs 6 months
after treatment and yearly from that point. Assess-
ment was aided by colour photographs and fluores-
cein angiograms. (3) Vitreous haemorrhage and
other complications including uveitis, glaucoma,
and retinal detachment. (4) Blindness: eyes were
accepted as blind as an end result of the proliferative
process and/or vitreous haemorrhage if this involved
a fall of visual acuity to less than 6/60 on the
Snellen chart. This result had to be recorded on at
least two consecutive visits.

Patients were reviewed at intervals of 2 weeks,
1 month, and 4 to 6 months after the completion
of peripheral retinal ablation. Further assessment
included visual fields, retinal colour photography,
and fluorescein angiography.
Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy during pregnancy

Results

For the purposes of the study the 11 pregnant patients were compared with the nonpregnant women contained in the randomised, controlled trial of peripheral retinal ablation. Exclusions from the study were made if the patient conformed to one of the following criteria: (i) postmenopausal, at first attendance with proliferative retinal changes; (ii) pregnancy had occurred since proliferative retinal changes were first identified but prior to assessment in our clinic.

Finally the 2 groups of women were compared with all the men entered into the initial randomised, controlled study. The findings are shown in Table 1.

Table 1 Population studies of patients in comparative groups

<table>
<thead>
<tr>
<th></th>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonpregnant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (mean) in years</td>
<td>26</td>
<td>36.5</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>17.7-25</td>
<td>17-45</td>
</tr>
</tbody>
</table>

OPTIC DISC NEOVASCULARISATION

Regression of new vessels at the optic disc was assessed on the basis of status at initial examination and subsequent change recorded 6/12 after completion of photocoagulation, or, in the case of the pregnant women, 6/12 after the end of the gestational period (Figs. 1–6).

In the pooled female groups all patients experienced a measurable degree of vessel regression, while the male group had 7.4% of cases in which the neovascular situation either remained stable or deteriorated. A less than significant response was measured in 36.4% of pregnant women, 33% of nonpregnant, and 9.2% of men. A significant improvement in vessel status was recorded in 63.6% of pregnant women, 66% of nonpregnant, and 83% of men (Table 2a, b).

Table 2a Initial grading of retinopathy at optic disc (according to classification of Hercules et al.17)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Pregnant</th>
<th>Nonpregnant</th>
<th>Males</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>12</td>
<td>21</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>5</td>
<td>29</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>11</td>
<td>21</td>
<td>54</td>
</tr>
</tbody>
</table>

Table 2b Percentage regression of new vessels at optic disc (<50% is considered to be nonsignificant)

<table>
<thead>
<tr>
<th>Vessel regression</th>
<th>Pregnant</th>
<th>Nonpregnant</th>
<th>Males</th>
</tr>
</thead>
<tbody>
<tr>
<td>100%</td>
<td>2</td>
<td>8</td>
<td>19</td>
</tr>
<tr>
<td>&gt;50%</td>
<td>5</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>&lt;50%</td>
<td>4</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Same or advancing</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
</tbody>
</table>

Fig. 1 Fluorescein angiogram showing early papillovitreal neovascularisation of the disc at the end of the first trimester of pregnancy.

Fig. 2 Fluorescein angiogram of the fundus in Fig. 1 at 28 weeks. Peripheral retinal photocoagulation has been undertaken. Laser scars are either 1 or 12 weeks old. There has been an increase in new vessels along the temporal arcades.
VITREOUS HAEMORRHAGE
The mean time to vitreous haemorrhage, and the occurrence of this event, were recorded in both treated and control eyes. The results are shown in Table 3a, b.

In the randomised, controlled trial, the mean time to the onset of vitreous haemorrhage from the start of treatment was evaluated in treated and control eyes. The difference in mean time to vitreous haemorrhage, expressed in years, for all treated groups and for the control groups was very highly significant (Mann-Whitney U test, P<0.0001).

BLINDNESS
Table 4 outlines the number of eyes in each of the 3 groups which proceeded to blindness within the first 3 years after photocoagulation.

In the randomised, controlled trial the difference in proportions between treated and control eyes

---

**Fig. 3** Fluorescein angiogram shows the fundus of Fig. 1 6 months after the successful completion of pregnancy. There is no further advance of the 'arcuate' papillovitreal complex, and the vascular component is increasingly attenuated.

**Fig. 4** Fluorescein angiogram showing extensive peripapillary neovascularisation with early glial tissue deposition after 12 weeks of pregnancy. Old argon laser burns are seen in the nasal fundus. This treatment was undertaken in the active phase of new vessel growth 3 weeks prior to pregnancy.

**Fig. 5** Fluorescein angiogram showing the fundus of Fig. 4 with further argon laser applications in lightly treated and untreated areas at 28 weeks. There has been a slight extension of the neovascular complex.

**Fig. 6** Fluorescein angiogram showing the fundus of Fig. 4 6 months after successful completion of pregnancy. More extensive photocoagulation has been undertaken and there has been a slight reduction in neovascular tissue.
Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy during pregnancy

Table 3a Patients developing vitreous haemorrhage after cessation of photocoagulation therapy

<table>
<thead>
<tr>
<th></th>
<th>Pregnant</th>
<th>Nonpregnant</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both eyes</td>
<td>4</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>Treated eye</td>
<td>2</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Control eye</td>
<td>4</td>
<td>3</td>
<td>18</td>
</tr>
<tr>
<td>Absent</td>
<td>1</td>
<td>3</td>
<td>21</td>
</tr>
<tr>
<td>Total no. of patients</td>
<td>11</td>
<td>21</td>
<td>54</td>
</tr>
</tbody>
</table>

Table 3b Comparison of vitreous haemorrhage events in the female groups

<table>
<thead>
<tr>
<th>Vitreous haemorrhage events (1 or more)</th>
<th>Present</th>
<th>Not present</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated eyes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>'Pregnant'</td>
<td>7</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>'Nonpregnant'</td>
<td>5</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Control eyes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>'Pregnant'</td>
<td>8</td>
<td>3</td>
<td>0.0396</td>
</tr>
<tr>
<td>'Nonpregnant'</td>
<td>7</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Pooled 'pregnant' eyes</td>
<td>15</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Pooled 'nonpregnant' eyes</td>
<td>12</td>
<td>30</td>
<td></td>
</tr>
</tbody>
</table>

*Ho preg. nonpreg. = pregnant not significantly greater than non-pregnant.

Table 4 Patients proceeding to blindness (<6/60 on the Snellen chart, at 2 successive 4-month visits) within 3 years

<table>
<thead>
<tr>
<th></th>
<th>Pregnant</th>
<th>Nonpregnant</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>% Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neither eye blind</td>
<td>5</td>
<td>45·5</td>
<td>16</td>
</tr>
<tr>
<td>Treated eye blind</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Control eye (only)blind</td>
<td>5</td>
<td>45·5</td>
<td>4</td>
</tr>
<tr>
<td>Both eyes blind</td>
<td>1</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>All untreated eyes blind</td>
<td>6</td>
<td>54·5</td>
<td>5</td>
</tr>
</tbody>
</table>

Table 3a Patients developing vitreous haemorrhage after cessation of photocoagulation therapy.

proceeding to blindness within 3 years was significant in all but the late stages of the proliferative process (McNemar's modified \( \chi^2 \) test).

**Visual Acuity**

No demonstrable significant difference between the retention of initial visual acuity in treated or control female eyes was demonstrated at any time (by Wilcoxon tests). When pregnant and nonpregnant patients were compared it was found that after 2 years there was a significant difference between the treated eyes of the nonpregnant and pregnant groups. The mean cumulative deterioration of visual acuity was greater in the pregnant group. The same result was also seen at 2 years when the control eyes of the above 2 groups were compared (Fig. 7).

Fig. 7 Top: Three-year comparison of mean cumulative deterioration of visual acuity in male diabetics subjected to randomised unilocular panretinal photocoagulation for proliferative diabetic retinopathy involving the optic disc. Centre: Three-year comparison of mean cumulative deterioration of visual acuity between randomised eyes in pregnant diabetics \( (T= \text{treated}; \ C= \text{control eyes}) \). Bottom: Three-year comparison of mean cumulative deterioration of visual acuity in nonpregnant diabetic women subjected to unilocular, randomised, panretinal photocoagulation (nulliparous or more than 5 years regular menstruation prior to assessment).
Fig. 8 Mean cumulative deterioration of visual acuity contrast between all treated and control female eyes over the 3-year period following panretinal photocoagulation.

There was a statistically significant difference in mean cumulative deterioration of visual acuity between treated and untreated eyes (Table 5), in the female group studied (Fig. 8). This difference was found at all time-intervals measured, and is outlined below:

<table>
<thead>
<tr>
<th>By Wilcoxon tests at</th>
<th>Between treated and control eyes</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/12</td>
<td>P = 0.0297</td>
</tr>
<tr>
<td>9/12</td>
<td>P = 0.0306</td>
</tr>
<tr>
<td>2 years</td>
<td>P = 0.0025</td>
</tr>
<tr>
<td>3 years</td>
<td>P = 0.0076</td>
</tr>
</tbody>
</table>

Discussion

No clear-cut conclusions regarding the effects exerted by pregnancy on proliferative retinal change in diabetes have been reached, because few centres have treated any significant number of patients, and the problem is further compounded by the fact that the natural history of the retinal process frequently spans a 9-month period. The outcome of pregnancy is certainly related, however, to the presence of proliferative retinal change, as the severity of this change correlates quite closely with the presence of microangiopathy elsewhere in the body (especially the kidneys).

It has not been possible clearly to elucidate an answer to the question, is pregnancy in some way exerting a trigger influence in the proliferative process? What does seem certain is that a considerable proportion of patients who show a progression of retinopathy during pregnancy will show regression after delivery. Unfortunately, this is clearly not the case in the patients who show proliferative, as opposed to background, retinal changes. This is particularly true in the group presently discussed, where the proliferative changes are the most sinister and vision-threatening of all, because neovascularisation of the optic disc is present.

The present series has shown that, even with a peripheral retinal ablation procedure utilising between 1200 and 2500, 500 μm spot-diameter impact-burns, a few beneficial effects are conferred. Significant improvement in neovascular status (>50%) at the optic disc occurred in 63-6% of cases. Yet this did significantly reduce the frequency of severe vitreous haemorrhage (≥2 lines fall, in visual acuity, on the Snellen chart). Again, no beneficial or protective effect occurred within 3 years, when eventual visual acuity was examined. There was evidence of a statistically significant difference in mean cumulative deterioration of visual acuity between treated and control eyes over 1-2 years.

Any woman with the retinal vascular problems ensuing from optic disc neovascularisation runs a
Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy during pregnancy

grave risk in assuming the added metabolic burden of pregnancy. In the later stages, hypertension and albuminuria may first appear. It is at this point in the pregnancy when proliferative change may appear to be contained by photocoagulation. Yet such reduction in the progressive nature of this process seems to have conferred little benefit visually to the patients examined in this series. If pregnancy is permitted to run its course, scrupulous care is necessary for the successful management of the diabetic. It is thus worthwhile to pursue the potentially protective effects of panretinal photocoagulation with a more extensive form of application (up to 6000 impact burns) than described in the patients from this series. It is the authors’ considered opinion that therapeutic abortion and sterilisation are not justified for ophthalmic reasons.

Our thanks are due to Dr E. S. Rosen and Mr A. Stewart Scott for their support and permission to treat patients in their care.

References

Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy during pregnancy.

B L Hercules, M Wozencroft, I I Gayed and J Jeacock

Br J Ophthalmol 1980 64: 87-93
doi: 10.1136/bjo.64.2.87

Updated information and services can be found at:
http://bjo.bmj.com/content/64/2/87

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/